AV965

AV-965 is a pharmacological compound being studied as a selective antagonist of the serotonin 5-HT_1A receptor, with potential applications in neuropsychiatric disorders such as cognitive impairment and schizophrenia.

Mechanism of action

AV-965 acts by blocking the 5-HT_1A receptor, a G protein-coupled receptor prevalent in the brain, especially in the raphe nuclei (where it acts as an autoreceptor) and in limbic and cortical regions (where it functions as a heteroreceptor). Antagonism of 5-HT_1A autoreceptors can disinhibit serotonergic neuron firing, potentially enhancing serotonin release and improving cognitive and behavioral outcomes in conditions marked by reduced serotonergic tone.

Clinical development

AV-965 has entered early clinical trials, with Phase I studies in healthy volunteers demonstrating a favorable safety and tolerability profile.

Potential therapeutic indications

The compound is under investigation for the treatment of cognitive impairment, particularly in schizophrenia and possibly Alzheimer’s disease. The rationale for targeting the 5-HT_1A receptor is supported by research showing its influence on cognition, mood, and anxiety.

Current research

Avera Pharmaceuticals is developing AV-965. Selective 5-HT_1A receptor modulation is a promising strategy in neuropsychiatric drug development, as both agonists and antagonists have shown potential in preclinical models for improving cognitive and behavioral symptoms.

See Also

• Aripiprazole